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Abstract
Purpose The adenosine A3 receptor (A3R) is involved in
cardiovascular, neurological and tumour-related patholo-
gies and serves as an exceptional pharmaceutical target
in the clinical setting. A3R antagonists are considered
antiinflammatory, antiallergic and anticancer agents, and
to have potential for the treatment of asthma, COPD,
glaucoma and stroke. Hence, an appropriate A3R PET
tracer would be highly beneficial for the diagnosis and
therapy monitoring of these diseases. Therefore, in this
preclinical in vivo study we evaluated the potential as a
PET tracer of the A3R antagonist [18F]FE@SUPPY.
Methods Rats were injected with [18F]FE@SUPPY for
baseline scans and blocking scans (A3R with MRS1523
or FE@SUPPY, P-gp with tariquidar; three animals each).
Additionally, metabolism was studied in plasma and brain.
In a preliminary experiment in a mouse xenograft model
(mice injected with cells expressing the human A3R; three
animals), the animals received [18F]FE@SUPPY and
[18F]FDG. Dynamic PET imaging was performed (60 min
in rats, 90 min in xenografted mice). In vitro stability of
[18F]FE@SUPPY in human and rat plasma was also
evaluated.
Results [18F]FE@SUPPY showed high uptake in fat-rich
regions and low uptake in the brain. Pretreatment with
MRS1523 led to a decrease in [18F]FE@SUPPY uptake
(p=0.03), and pretreatment with the P-gp inhibitor
tariquidar led to a 1.24-fold increase in [18F]FE@SUPPY
uptake (p=0.09) in rat brain. There was no significant
difference in metabolites in plasma and brain in the
treatment groups. However, plasma concentrations of
[18F]FE@SUPPY were reduced to levels similar to those
in rat brain after blocking. In contrast to [18F]FDG uptake
(p=0.12), the xenograft model showed significantly in-
creased uptake of [18F]FE@SUPPY in the tissue masses
from CHO cells expressing the human A3R (p=0.03).
[18F]FE@SUPPY was stable in human plasma.
Conclusion Selective and significant tracer uptake of
[18F]FE@SUPPY was found in xenografted mice injected
with cells expressing human A3R. This finding supports
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the strategy of evaluating [18F]FE@SUPPY in “humanized
animal models”. In conclusion, preclinical evaluation
points to the suitability of [18F]FE@SUPPY as an A3R
PET tracer in humans.
Keywords Adenosine A3 receptor . Small-animal PET .
[18F]FE@SUPPY . Xenograft . Efflux transporter . Tumour
marker
Introduction
Adenosine is one of the main “speed limiters” in the
human body contributing to most energy-associated pro-
cesses. It unfolds its various effects via A1, A2A, A2B
and A3 receptors. Due to the late discovery of the
adenosine A3 receptor (A3R) in the 1990s, quantitative
data regarding its distribution and density in vivo is still
sparse. Besides its broad involvement in cardiovascular
and neurological pathologies, recent studies indicate a
prevalent association of A3R in tumour-related diseases.
A3R has been reported to be especially pronounced in
prostate, breast and colon carcinoma and melanoma [1].
Surprisingly, although the involvement of A3R in tu-
mour genesis, and cardiovascular and neurological pa-
thologies is undisputed, no antagonists have so far
reached clinical trials. Until recently, there were few
radioligands for A3R available ([125I]AB-MECA, an
A3 agonist, being one), and no PET ligands for the
imaging and evaluation of A3R. Nevertheless, future
clinical applications of suitable PET tracers can be
envisaged, e.g. as tumour markers for colon, breast
and prostate carcinoma and melanoma, which today
are diseases with high mortality.
We therefore in t roduced the A3R antagonis t
[18F]FE@SUPPY (5-(2-[18F]fluoroethyl)-2,4-diethyl-
3-(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate)
as the first PET tracer for A3R [2, 3]. Meanwhile, a second
potential PET radiotracer has been presented, radiolabelled
with 76Br [4]. Furthermore, we converted the fluoroethyl ester
[18F]FE@SUPPY into the f luoroethyl th ioes ter
[ 1 8 F ] F E@ S U P P Y: 2 ( 5 - e t h y l 2 , 4 - d i e t h y l -
3-((2-[18F]fluoroethyl)-sulfanylcarbonyl)-6-phenylpyridine-
5-carboxylate), to serve as a second potential A3R PET tracer
[5, 6]. Recently, a series of 11C-labelled 1,2,4-triazolo[4,
3-α]quinoxalin-1-one derivatives were synthesized as candi-
date PET radioligands for A3R [7].
[18F]FE@SUPPY displays high affinity for human
A3R (Ki 4.2 nM), whereas its affinity towards rat A3R
is rather low (Ki 600 nM) [8]. This fact can be explained
by the species differences regarding the A3R protein, the
difference between humans and rats being pronounced
with a sequence homology of the proteins of only 72 %
[9]. Furthermore, binding studies have revealed affinities
of FE@SUPPY for human A1R and A2AR in the mi-
cromolar range, severalfold lower than towards human
A3R [10].
Therefore the results of the preclinical evaluation of
[18F]FE@SUPPY seemed quite promising: successful
radiopreparation of [18F]FE@SUPPY with satisfactory yields
and good specific radioactivity in an automated setup allowed
a series of preclinical evaluations [2, 3]. The ex vivo
biodistribution follows mainly the mRNA pattern of A3 de-
scribed previously [3], except for the lack of pronounced
tracer uptake in rat testes [11]. Ex vivo metabolite studies in
rats have shown metabolites to a certain extent in the blood
[12], and logP assessment has shown high lipophilicity of the
title compound [6]. Autoradiographic in vitro competition
experiments on human and rat brain tissues with [125I]AB-
MECA have confirmed the comparability of the title com-
pound FE@SUPPYand the commercially available and high-
ly selective A3 antagonist MRS1523 [13]. Furthermore,
biodistribution in rats shows that brain-to-blood ratios in-
crease over time [3]. Hence, we aimed to investigate the
in vivo behaviour of [18F]FE@SUPPY using small-animal
PET in rats and xenografted mice. Additionally, keeping in
mind the differences between these species, we wanted to
assess the in vitro stability of [18F]FE@SUPPY in human
and rat plasma. In detail, the aims of the study were:(1)
baseline small-animal PET scans, (2) small-animal PET scans
with A3R blocking, (3) examination of potential influence of
the efflux system (P-gp), (4) investigations regarding a xeno-
graft mouse model (with inoculated cells expressing the hu-
man A3R), and (5) in vitro stability of [18F]FE@SUPPY in
human and rat plasma.
Materials and methods
Tracer preparation
Radiosynthesis of [18F]FE@SUPPY was performed in a fully
automated synthesizer (TRACERlab FxFN; GE Healthcare) as
described elsewhere [2, 3].
Chemicals
All chemicals were of analytical grade and obtained from
Sigma-Aldrich Chemie GmbH (Schnelldorf, Germany) or
Merck KGaA (Darmstadt, Germany). Isoflurane was obtained
from Baxter Vertriebs GmbH (Vienna, Austria). Tariquidar
dimesylate (TQD) was kindly provided by Dr. Erker (Depart-
ment of Medicinal Chemistry, University of Vienna, Austria).
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Primary antibody (Anti-Adora3, HPA 028568) was obtained
from Santa Cruz Biotechnology, CA; and the avidin-biotin-
complex (Vectastain ABC kit PK 4001), aqueous mounting
medium (VectaMount™) and AEC solution (AEC substrate
kit for peroxidase, SK-4200) were purchased from Vector
Laboratories, CA.
Cell lines
The Chinese hamster ovary cell line CHO-K1 (CCL-61) was
obtained from ATCC and the CHO cell line, stably expressing
human A3R (CHO-A3) was a generous gift from Prof. Karl-
Norbert Klotz (University of Würzburg, Germany) [14]. All
cell lines were grown and handled according to standard
protocols.
Animals
The study was approved by the local Animal Welfare Com-
mittee and all study procedures were performed in accordance
with the Austrian Animal Experiments Act (LF1-TVG-34/
040-2008). All efforts were made to minimize pain and dis-
comfort as well as the number of animals.
Adult male Sprague-Dawley rats (Him:OFA; Animal Re-
search Institute, Himberg, Austria) weighing 307±35 g were
kept under controlled environmental conditions (22±1 °C,
40 – 70 % humidity, 12-h light/dark cycle) with free access
to standard laboratory animal diet and tap water. Before being
used in the experiments, the animals were allowed to adapt to
the new conditions for at least a week. Prior to each experi-
ment, the animals were placed in a chamber containing 2.5 %
isoflurane in oxygen. When unconscious, the animals were
taken from the chamber and kept under anaesthesia with 1.8%
isoflurane administered via a mask during the whole experi-
ment. Pathogen-free, female NMRI-nu/nu mice (Taconic,
Denmark) weighing 28.1±0.8 g were housed under sterile
conditions. Mice were injected subcutaneously into both up-
per flanks with 100 μL of a cell suspension in phosphate-
buffered saline containing 106 CHO cells (right side) or 106
CHO-A3 cells (left side). During the imaging periods of 60 or
90 min (rats or xenografted mice, respectively) the isoflurane
level was adjusted depending on the depth of anaesthesia. A
humidifier was used to moisten the gas mixture before sup-
plying it to the animal.
Small-animal PET
Experimental procedure
A microPET Focus220 scanner (Siemens, Medical Solutions)
was used for the experiments. It has 168 detector modules
providing a 7.6-cm axial and 22-cm transaxial field of view.
The resolution of the reconstructed images (filtered back
projection) was 1.3 mm (full-width at half-maximum) in the
central field of view and remained under 2 mm within the
central 5 cm diameter field of view [15]. For PET imaging two
groups of animals (rats and xenografted mice) were investi-
gated. Rats were divided into four groups. The first group
received vehicle (dimethyl sulphoxide, DMSO) intravenously
via a lateral tail vein 30 min prior to radiotracer administration
(three animals, 14.3 – 70.1 MBq, 0.2604±0.06 μg). The
second group received MRS1523 – a selective A3R antago-
nist – at a dose of 2 mg/kg body weight (dissolved in DMSO,
4 mg/mL) intravenously via a tail vein 30 min prior to radio-
tracer administration (three animals, 18.8 – 59.1MBq, 0.3443
±0.05 μg). The third group received unlabelled title com-
pound FE@SUPPY (dissolved in DMSO, 4 mg/mL) at a dose
of 2 mg/kg 30min before tracer administration (three animals,
9.7 – 16.1 MBq, 0.3926±0.04 μg). In the final study group,
the effect of P-glycoprotein inhibition was assessed by intra-
venous administration of 15mg/kg TQD (freshly dissolved on
each experimental day in 2.5 % aqueous dextrose solution and
injected intravenously via a tail vein at a volume of 3 mL/kg
over 1 min) 60 min prior to tracer administration (three ani-
mals, 13.9 – 26.8 MBq, 0.7451±0.11 μg).
Anaesthetized animals were positioned in the imaging
chamber of the microPET scanner, which was kept at 38 °C
throughout the experiment. A stereotactic holder attached to
the bed, consisting of ear plugs and a tooth bar, was used to fix
the animal's head to ensure a reproducible position during the
PET studies. [18F]FE@SUPPY (27.91±13.82 MBq) dis-
solved in 0.48±0.22 mL phosphate-buffered saline (pH 7.4)
was administered as a bolus via a tail vein. Dynamic PET
imaging was performed over 60 min in all animals. At the end
of the PET scan the animals were killed, a terminal blood
sample was collected and whole brains were removed for
testing of metabolite stability.
Xenograft mouse model
Around 17 days after cell inoculation, animals in the xenograft
group were positioned in the imaging chamber and a dynamic
90-min PETscanwas initiated at the start of [18F]FE@SUPPY
injection (2.21±0.75 MBq dissolved in 100 μl physiological
saline, pH 7.4; three animals) via a tail vein under isoflurane
anaesthesia (2 %). Additionally, in this group, [18F]FDG PET
was performed 1 day prior to the [18F]FE@SUPPY experi-
ments. As animal handling has been found to have a consid-
erable impact on [18F]FDG PET results, it was standardized
for all animals [16, 17]. In brief, mice were deprived of food
for 6 – 8 h before [18F]FDG injection via a tail vein. Mice had
access to drinking water at all times. Body warming was
achieved by placing the entire cage on a heating pad kept at
38 °C. Warming was started around 30 min before tracer
injection and was continued throughout the uptake and imag-
ing period. [18F]FDG (6.03±1.31 MBq dissolved in 100 μL
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physiological saline, pH 7.4; three animals) was injected via a
tail vein under isoflurane anaesthesia (2 %). Mice were kept
under isoflurane anaesthesia throughout the whole uptake and
imaging period. A 10-min static image was acquired at 1 h
after [18F]FDG injection. Dynamic PET imaging was per-
formed over 90 min in xenografted animals. At the end of
the PET scan the animals were killed and tumours were
resected for staining purposes.
PET data analysis
For all PET scans (rats and xenografted mice), list mode data
were acquired with an energy window of 350 – 750 keV (rats)
or 250 – 750 keV (mice) and a 6-ns timing window. Before
each PET scan, a transmission scan using a 57Co point source
was recorded over 10 min. The PET data from the 60-min
dynamic scans were sorted into three-dimensional sinograms
according to the following frame sequence: 6×20 s, 5×60 s,
4×120 s, 3×300 s and 3×600 s. For the 90-min scans (in the
xenografted mice) the following frame sequencewas used: 8×
5 s, 2×10 s, 2×30 s, 3×60 s, 2×150 s, 2×300 s, 4×600 s and
2×900 s. PET images were reconstructed by Fourier rebinning
followed by filtered back projection with a ramp filter. The
resulting voxel size was 0.6×0.6×0.8 mm for rats or 0.4×
0.4×0.8 mm for mice. The standard data correction protocol
(normalization, attenuation and decay correction) was applied
to the data. A calibration factor for converting units of
microPET images into absolute radioactivity concentration
units was first generated by imaging a phantom filled with a
known concentration of [18F]FDG.
Rat brains were manually outlined on multiple planes
of the PET summation images using the image analysis
software PMOD 3.1 (Pmod Ltd, Zürich, Switzerland) or
Amide [18]. Volumes of interest in the brain or solid
tissue mass (xenografts) were transferred to the PET
images of the individual time frames and time–activity
curves (TACs) expressed in units of kilobecquerels per
millilitre were calculated. To facilitate comparison of
TACs of different animals, radioactivity concentrations
were normalized to dose and weight and expressed as
standardized uptake value (SUV, %ID/cm3 or %ID/g).
For each TAC, the area under the curve (AUC, %ID/
cm3·min or %ID/g·min) from time zero to the last obser-
vation point was calculated using the OriginPro 7.5G




To determine the influence of the four treatments (vehicle,
MRS1523 , FE@SUPPY, TQD ) o n u p t a k e o f
[18F]FE@SUPPY, stability was assessed in plasma and brain
60 min after tracer injection. Final blood samples (3 mL) were
collected in heparin-buffered tubes, rat brains were washed
with ice-cold water and homogenized in 0.9 % aqueous NaCl
solution (1 mL) using an IKA T10 basic Ultra-turrax (IKA
Laboratory Equipment, Staufen, Germany). Blood and brain
homogenate probes were each spiked with unlabelled
FE@SUPPY (0.5 mg/ml), and centrifuged (4,000 rpm,
5 min) to separate cellular components. Sample clean-up
was performed by vortexing plasma with the equivalent
amount of methanol/acetonitrile (9:1) for 1 min and by sub-
sequent ultracentrifugation (10,000 rpm, 5 min) to remove
precipitated proteins. The supernatants obtained were
analysed by radio-HPLC (Agilent, Boeblingen, Germany)
equipped with a series 1100 autosampler, a series 1200 qua-
ternary pump, a series 1200 diode array detector and a lead-
shielded BGO radiodetector. A Chromolith® Performance
RP-18e (100×4.6 mm, 5 μm) column with a Chromolith®
Performance RP-18e (4 x4 mm, 5 μm) precolumn was eluted
at a flow rate of 2 mL/min using a mobile phase consisting of
60 % acetonitrile and 40 % water/acetic acid 97.5:2.5 and
32 mM ammonium acetate, pH 3.5. UV detection was per-
formed at a wavelength of 254 nm. The retention time of
[18F]FE@SUPPY was 4.6 – 5.9 min (UV detection and
radiodetection).
In vitro plasma stability
Experiments were conducted following a standard protocol
[19]. Briefly, [18F]FE@SUPPY was added to lithium-
heparinized human or rat plasma and after predetermined
times (0, 60 and 120 min), the incubation mixture was
eluted through a preconditioned SPE cartridge. The
washed and newly eluted eluate solutions were injected
into the radio-HPLC system (HPLC system as described
in the section Ex vivo stability). The stationary phase was
an analytical HPLC column LiChrospher LICHROCART®
RP-18e (5 μm), 125×4 mm precolumn, and the mobile
phase consisted of sodium citrate tribasic dehydrate (buff-
ered at 0.034 M, pH 2.5)/acetonitrile 32:68 at a flow rate of
2 mL/min. Samples were incubated with a Thermomixer
Compact from Eppendorf (Vienna, Austria) and centri-
fuged with a Universal 30 RF centrifuge from Hettich
(Tuttlingen, Germany).
Statistical analysis
All values are given as arithmetic means±standard de-
viation (unless stated otherwise). To determine potential
significant differences, a two-tailed t test with α=0.95
and analysis of variance testing were performed using
the statistics add-on in Windows® Excel 2010. A value
of P≤0.05 was considered significant.
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Results
Tracer preparation
Starting from 51±25G Bq of [18F]fluoride, 8±2 GBq of
formulated [18F]FE@SUPPY was achieved. Radiochemical
purity was greater than 98 % and the specific activity at the
end of synthesis was 61±12 GBq/μmol. The only radioactive
contaminant was [18F]f luor ide. The ident i ty of
[18F]FE@SUPPY was confirmed by HPLC with coinjection




[18F]FE@SUPPY showed generally high uptake in fat-rich
regions such as the harderian and lacrimal glands (consistent
uptake over 60 min) and low uptake in the brain which
decreased after 10 – 15 min.
Blocking
Typical blocking scans of [18F]FE@SUPPY in male rats after
pretreatment with DMSO (vehicle) and MRS1523 are shown
in Fig. 1a, b. MRS1523 administration led to a significant
reduction (p=0.009) in peak brain activity of 34.1 % as
compared with DMSO administration (Fig. 2a). Unlabelled
FE@SUPPY administration led to a reduction in peak brain
activity of 16.7 % as compared with DMSO administration,
but the reduction did not reach statistical significance (p=0.1,
Fig. 2a). The AUCs followed the trend observed in the peak
brain activities following all four pretreatments. A 1.35-fold
higher AUC was found after DMSO administration as com-
pared to no treatment (p=0.016). MRS1523 administration
led to a 27.6 % reduction in AUC (p=0.03) as compared with
DMSO administration. Unlabelled FE@SUPPY administra-
tion led to a 5.4 % reduction in AUCs as compared with
DMSO administration.
Efflux inhibition
A typical blocking scan of [18F]FE@SUPPY in male rats after
pretreatment with TQD is shown in Fig. 1c. Peak brain activ-
ity was similar in the untreated (1.56±0.22 SUV) and the
TQD-treated group (1.53±0.01 SUV). Figure 2b shows brain
TACs from untreated and TQD-treated rats. P-gp inhibition
resulted in a 1.24-fold increase in the brain AUC relative to the
baseline scan (p=0.09).
Xenograft mouse model
TACs of [18F]FE@SUPPYuptake in the solid tissue masses in
mice injected with CHO or CHO-A3 cells are shown in
Fig. 3a. The AUCs extracted from the TACs for mice injected
with CHO-A3 cells showed an increased uptake of
[18F]FE@SUPPY of around 1.42-fold (p=0.03) in compari-
son with the AUCs for mice injected with CHO cells.
[18F]FDG uptake in the mice injected with CHO-A3 cells
was slightly higher than in those injected with CHO cells
(6.3 %ID/g versus 5.4 %ID/g, respectively) but the difference
did not reach statistical significance (p=0.12). PET summa-
tion images after [18F]FDG administration and after
[18F]FE@SUPPY administration are shown in Fig. 3b, c.
Metabolism
Ex vivo stability
To assess the influence of pretreatment, radiometabolites of
[18F]FE@SUPPY were determined by radio-HPLC in plasma
and brain from rats pretreated with DMSO vehicle,
MRS1523, FE@SUPPYor TQD. The amounts of radioactive
metabolites were inversely proportional to the amounts of
unchanged parent compound in both plasma and brain. At
Fig. 1 Sagittal, coronal and transverse images (summed over 60 min)
showing uptake of [18F]FE@SUPPY in rat brain: a baseline scan with
DMSO vehicle, b blocking with MRS1523 (2 mg/ml), c efflux inhibition
with tariquidar (15 mg/ml)
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60 min after tracer injection, plasma from rats pretreated with
DMSO, TQD, FE@SUPPY and MRS1523 contained 25.8±
5.3 %, 39.9±4.7 %, 32.4±5.6 % and 26.5±1.4 % of un-
changed [18F]FE@SUPPY, respectively (Table 1). At 60 min
after tracer injection, brain extracts from rats pretreated with
DMSO, TQD, FE@SUPPY and MRS1523 contained 43.7±
9.5 %, 55.2±7.0 %, 49.6±9.4 % and 37.8±4.3 % of un-
changed [18F]FE@SUPPY, respectively (Table 1). However,
there were no significant differences among the different
groups, for both plasma and brain. Total recovery of radioac-
tivity from blood and brain was 86 – 92 %.
a
























































Fig. 2 Time–activity curves (mean±SEM) of [18F]FE@SUPPY uptake
in rat brain (a) 30 min after adminstration of DMSO vehicle (closed
squares), 2 mg/kg ofMRS1523 (open circles) or 2 mg/kg of FE@SUPPY
(open triangles; three animals per group) and (b) 60 min after
adminstration of DMSO vehicle (closed squares) or 15 mg/kg of








Fig. 3 Uptake experiments in xenografted mice. a Time–activity curves
(mean±SEM) of [18F]FE@SUPPY in solid tissue masses resulting from
bilateral cell inoculation of parental CHO cells and CHO-A3 cells. The
solid masses from the injection of CHO-A3 cells show significantly
higher tracer uptake than the solid masses from the injection of CHO
cells (p=0.03). b [18F]FDGPETsummation (0 – 10min) images obtained
1 h after tracer administration. c Typical [18F]FE@SUPPY PET
summation (0–10 min) images. The respective radiation scales are
indicated with the images
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In vitro plasma stability
In human plasma, [18F]FE@SUPPY showed no degradation.
In rat plasma, 60 min and 120 min after addition of
[18F]FE@SUPPY, 18.7±3 % and 35.0±4 % of the radioac-
tivity, respectively, was frommetabolites The total recovery of
radioactivity from the plasma samples was >95 %.
Discussion
General
A3R is involved in cardiovascular and neurological patholo-
gies, and – as recently indicated – in tumour-related diseases.
Since it has been reported that the A3R protein is expressed at
particularly high levels in prostate, breast and colon carcinoma
and melanoma, future clinical applications of A3R PET
tracers can be envisaged, e.g. as imaging biomarkers for these
disease with high mortality [1]. Surprisingly, no A3R antago-
nists have yet reached clinical trial status, although they are
considered antiinflammatory, antiallergic and anticancer
agents, and to have potential for the treatment of asthma,
COPD, glaucoma and stroke [20]. Until recently, there were
no PET tracers available for the imaging and noninvasive
evaluation of A3R. Gessi et al. stated that “research in the
A3 field is still in its infancy, with several important and
challenging issues remaining to be addressed” [1]. Therefore,
we developed [18F]FE@SUPPY as the first PET tracer for
A3R. Radiopreparation and first preclinical evaluation includ-
ing biodistribution, in vitro metabolic stability studies, ex vivo
metabolism studies and in vitro autoradiography [2, 3, 6, 12,
13] showed quite promising results. This led us to the next
step of the in vivo evaluation of [18F]FE@SUPPY under
different conditions (baseline, specific blocking of A3R,
blocking of P-gp, mice inoculated with human A3R cell
xenografts) using small-animal PET and to assess in vitro
tracer stability in human and rat plasma (an overview of the
results of this evaluation of [18F]FE@SUPPY as a potential
A3R PET tracer is presented in Table 2).
Small-animal PET
Baseline
The high degree of accumulation of [18F]FE@SUPPY in fat-
rich regions might be explained by the high HPLClogD
7.4 of
4.04 [6]. Surprisingly, baseline conditions in the brain found
in this small-animal PET study did not reflect the increasing
uptake of the tracer in brain, which we expected on the basis of
a previous biodistribution study, in which we found that brain-
to-blood ratios increase over time [3].
It is noteworthy that there were differences between base-
line scans and vehicle scans: 1.35 times higher AUC for
vehicle as compared to baseline without vehicle. The vehicle
DMSO was necessary for dissolving the two A3R antagonists
MRS1523 and FE@SUPPY for pretreatment (final injected
Table 1 Metabolism of
[18F]FE@SUPPY in blood and
brain after pretreatment with
DMSO, MRS1523, FE@SUPPY
or TQD
Pretreatment Unchanged [18F]FE@SUPPYat 60 min (%) %ID/g at 60 min
Blood Brain Blood Brain
DMSO 25.81±5.3 43.73±9.6 0.0216±0.003 0.1132±0.0002
MRS1523 26.54±1.4 37.75±4.3 0.0145±0.002 0.0918±0.0001
FE@SUPPLY 32.44±5.7 49.64±9.4 0.0160±0.002 0.1273±0.0000
TQD 39.87±4.7 55.21±7.0 0.0214±0.004 0.1507±0.0005
Table 2 Preclinical evaluation
findings of [18F]FE@SUPPYand
its potential for use in the clinical
setting
aMetabolism in rats is six to eight
times faster than in humans;
therefore we assume that potential
metabolites in humans would not
be a problem, particularly since
they are not radioactive [3]
Findings Final Countdown
Affinity for human A3R 4.2 nM [8] Favourable
Radiosynthesis Reliable, good specific activity [2, 3] Favourable
Biodistribution in rats Followed mainly A3 pattern (except testes) [3] Good
Bone uptake in rats None [3] Favourable
Ex vivo metabolites in rats Blood and brain OKa
Stability in human and rat plasma Stable over 120 min in human plasma Favourable
Autoradiography in humans
and rats
High selectivity; FE@SUPPLY comparable
with MRS1523 [12]
Favourable
Xenograft model of human A3R Specific uptake in CHO-A3 solid mass (p≤0.03)
compared to [18F]FDG
Favourable
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volumes contained up to a maximum of 10 % DMSO). Tracer
uptake in brain was increased by the presence of DMSO,
which we explained by the fact that DMSO is a solubilizer,
and therefore may enhance blood–brain barrier permeability.
Blocking
Blocking of [18F]FE@SUPPY with MRS1523 led to signifi-
cant displacement of peak brain activity and AUCs (p=0.009,
p=0.03), whereas FE@SUPPY pretreatment led to displace-
ment that did not reach a significant level. This observation
can be explained by the 5.31-fold higher affinity of MRS1523
for rat A3R (Ki 113 nM) compared with that of FE@SUPPY
(Ki 600 nM) [21].
Efflux inhibition
TQD was administered at a dose that has been shown to
completely inhibit P-gp at the blood–brain barrier [22], lead-
ing to 25 % increased brain uptake of [18F]FE@SUPPY in the
brain relative to the vehicle treatment (p=0.09). This suggests
that P-gp efflux plays a role in limiting brain uptake of
[18F]FE@SUPPY in rats.
Xenograft mouse model
[18F]FE@SUPPY showed significantly increased uptake in
the tissue mass from CHO cells expressing the human A3R
compared with the tissue mass from parental CHO cells (p=
0.03). This effect was not observed with [18F]FDG, although
tissue masses from both transfected and parental CHO cells
had high metabolic consumption due to their high prolifera-
tion rates. This indicates that, in contrast to [18F]FDG (p=
0.12), a gold standard tracer for the in vivo diagnosis of cancer
and tumour diseases, [18F]FE@SUPPY is able to distinguish
between parental CHO cells and CHO cells expressing the
human A3R. The results in this preliminary xenograft model,
keeping in mind the high affinity of [18F]FE@SUPPY for the
human A3R (Kih 4.2 nM), support the strategy of evaluating
[18F]FE@SUPPY in “humanized models”.
Metabolism
Ex vivo stability
The metabol ic s ta tus ( in vi t ro and ex vivo) of
[18F]FE@SUPPY was characterized in a previous study
[12]. For the in vivo experiments described here, an additional
metabolic analysis was performed to exclude a possible influ-
ence of different blocking conditions on the uptake and met-
abolic behaviour of [18F]FE@SUPPY. Radioactive metabo-
lites were found in both rat blood and rat brain under all four
treatment conditions (vehicle, MRS1523, FE@SUPPY and
TQD). However, all observed changes in metabolism were
statistically insignificant, and a significant influence of the
uptake caused by changes in metabolism can therefore be
excluded. Nevertheless, plasma concentrations at 60 min after
injection showed similar reductions to those after the blocking
treatments in rat brains (36 % with MRS1523, 27 % with
FE@SUPPY). The calculated uptake in plasma ranged from
0.014±0.001 %ID/g (MRS1523) to 0.022±0.003 %ID/g
(vehicle); these values are not significantly different. Brain
to blood uptake ratios ranged from 5.2 (baseline) to 7.9
(FE@SUPPY). Similar values were found in our
biodistribution experiments (up to 5.4) [3].
Taking into account the data from the previous metabolic
ex vivo study [12], in which we found 30 % parent compound
left in plasma and nometabolites of [18F]FE@SUPPY in brain
at 30 min after injection, and knowing that metabolism in rats
is several times faster than in humans, we conclude that
[18F]FE@SUPPY should be stable for the typical time-span
of a clinical investigation in humans.
In vitro plasma stability
In rat plasma, degradation of [18F]FE@SUPPY led to
19 – 35 % radioactive metabolites over the observation period
of 120 min, which is in a similar range to that observed
ex vivo. In human plasma, [18F]FE@SUPPY was stable over
the observation period of 120 min, which is encouraging for
potential future applications in humans.
Conclusion
It is known that A3R is available only at low densities in most
tissues and at especially low densities in the central nervous
system [23], and there are species differences regarding the A3R
protein between rats and humans, resulting in reduced affinities
of 1,4-dihydropyridine analogues (including MRS1523 and
FE@SUPPY) for rat A3R. However, since A3R is involved in
cardiovascular, neurological and tumour-related pathologies
and could serve as an exceptional pharmaceutical target in the
clinical setting, the purpose of the present study was the pre-
clinical evaluation of [18F]FE@SUPPY in vivo.
[18F]FE@SUPPY showed high uptake in fat-rich regions
and low uptake in brain due to a significant influence of efflux
transporters. Therefore, we conclude that mechanisms in-
volved in the observed tracer uptake in rat brain were partly
specific (significantly blockable with MRS1523, blockable
but not significantly with FE@SUPPY) and the rat animal
model in general is not suitable for the evaluation of
[18F]FE@SUPPY in vivo. Nevertheless, in xenografted mice
[18F]FE@SUPPY showed significantly increased uptake in
the tissue mass from CHO cells expressing human A3R
compared with that in the tissue mass from parental CHO
cells (p=0.03). In contrast, [18F]FDG, the gold standard tracer
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for inflammation and tumour imaging, did not show signifi-
cantly increased uptake in this model (p=0.12) although tissue
masses from both transfected and parental CHO cells showed
similarly elevated levels of metabolic consumption due to
their similar growth rate. This finding supports the strategy
of evaluating [18F]FE@SUPPY in “humanized animal
models”. Furthermore, no metabolites of [18F]FE@SUPPY
were observed until 30 min after tracer administration in rat
brain [12] and nometabolites were observed in human plasma
in vitro. Since usually metabolism in rodents is several times
faster than in humans, we expect [18F]FE@SUPPY to be
stable for the typical time-span of a clinical investigation in
humans. However, final proof of stability will only be provid-
ed in a human setting.
In summary, as a final conclusion, the main findings of the
preclinical evaluation of [18F]FE@SUPPY are shown in Ta-
ble 2. All in all, they point in favour of the suitability and
specificity of [18F]FE@SUPPY as a PET tracer for the non-
invasive visualization of A3R and A3R-related pathologies in
humans. Therefore, as a follow-up study we aim to evaluate
[18F]FE@SUPPY in animal models with different implanted
human tumour cell lines expressing A3R under baseline and
blocking conditions.
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